PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

Inclusion criteria

• ✓. Age 18-75 (inclusive).
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and Estimated life expectancy of more than 3 months.
• ✓. Histopathological /cytological or diagnosed clinically confirmed locally advanced or metastatic HCC having undergone treatments recommended by the "Primary Liver CancerDiagnosis and Treatment Guidelines (2024 Edition)" ,which is refractory/relapsed after and/or intolerant of standard therapies (including targeted therapy and immunotherapy) or for which no subsequent standard therapy exists.
• ✓. At least one measurable lesion at baseline according to investigators Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1).
• ✓. Patients with injectable lesions (those suitable for direct injection or injection with the assistance of medical imaging), defined as follows: at least one injectable lesion in the skin, mucous membrane, subcutaneous tissue, lymph node or visceral organ with a longest diameter ≥10 mm.
• ✓. Subjects are willing to accept tumor rebiopsy in the process of this study.
• ✓. Barcelona Clinic Liver Cancer (BCLC) stage ≤C.
• ✓. Adequate organ function as defined by the following criteria:

Exclusion criteria